• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconGilead

Gilead

U.S. approves twice-a-year shot to prevent HIV but cuts to public health and foreign aid cloud its prospects
Health
U.S. approves twice-a-year shot to prevent HIV but cuts to public health and foreign aid cloud its prospects
By Lauran Neergaard and The Associated PressJune 19, 2025
A twice-yearly shot of this drug could help end AIDS — ‘it’s unprecedented’
Health
A twice-yearly shot of this drug could help end AIDS — ‘it’s unprecedented’
By Maria Cheng, María Verza and The Associated PressDecember 1, 2024
Brainstorm Health 2021-Gilead-Daniel O'Day
Conferences
Gilead’s remdesivir is now used to treat half of hospitalized COVID patients
By Sy MukherjeeApril 28, 2021
A line of syringes shown in silhouette against the AstraZeneca corporate logo.
Finance
AstraZeneca’s stock is soaring on COVID, but the pandemic has dented its growth
By Jeremy KahnNovember 6, 2020
Gilead remdesivir price
Newsletters
Gilead just got the first FDA coronavirus treatment approval, but there are still problems
By Sy MukherjeeOctober 22, 2020
Gilead remdesivir coronavirus FDA
Health
Gilead says remdesivir slashes coronavirus deaths. But it’s complicated
By Sy MukherjeeJuly 10, 2020
Brainstorm Health 2020-Eric Lefkofsky
Newsletters
Coronavirus exposes the trouble of scientific unknowns
By Sy MukherjeeJuly 10, 2020
Gilead remdesivir coronavirus FDA
Health
COVID treatment remdesivir will cost $520 per vial. But it may not be how much you pay
By Sy MukherjeeJune 29, 2020
Gilead coronavirus treatment drug Remdesivir
Health
Gilead to charge thousands for coronavirus treatment drug that critics say should cost $1
By Robert Langreth and BloombergJune 29, 2020
Gilead inhaled remdesivir trial
Health
Gilead’s next COVID-19 treatment advancement could keep patients out of hospitals
By Sy MukherjeeJune 22, 2020
AstraZeneca Gilead deal
Health
Rumors swirl about an AstraZeneca and Gilead megadeal—but it doesn’t make sense
By Sy MukherjeeJune 8, 2020
Will COVID-19 change how Big Pharma does clinical trials?
Magazine
Will COVID-19 change how Big Pharma does clinical trials?
By Erika FryMay 15, 2020
Antibody testing will be key—once we understand what the results mean
Health
Antibody testing will be key—once we understand what the results mean
By Sy MukherjeeMay 12, 2020
Gilead remdesivir price
Newsletters
Gilead’s moral (and financial) COVID-19 conundrum
By Sy MukherjeeMay 7, 2020
Gilead-Sciences-Remdesivir
Health
Remdesivir is the first coronavirus treatment. So why is Gilead’s stock plunging?
By Sy MukherjeeMay 1, 2020
1
  • 1
  • 2
  • 3
  • 4
4
Most Popular
Law
Egg companies made $1.22 billion in profit off a $6 carton — now they’re buying their way out of a price-fixing case with 53 million donated eggsplaceholder alt text
By Wyatte Grantham-Philips and The Associated PressJuly 2, 2026
AI
Meet the Zillennials: The luckiest micro-generation in the workforce, born between 1993 and 1998placeholder alt text
By Nick LichtenbergJuly 3, 2026
Economy
Economists have found an answer to slowing cognitive decline: Avoid retiring early, study findsplaceholder alt text
By Sasha RogelbergJuly 2, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.